메뉴 건너뛰기




Volumn 9, Issue 1, 2014, Pages 9-16

Maintaining Low BCR-ABL signaling output to restrict CML progression and enable persistence

Author keywords

BCR ABL; CML; Imatinib; Kinase inhibitors; Persistence

Indexed keywords

ARF PROTEIN; BCR ABL PROTEIN; IMATINIB; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

EID: 84896729095     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0196-8     Document Type: Review
Times cited : (11)

References (92)
  • 3
    • 0022544401 scopus 로고
    • The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
    • Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-4. (Pubitemid 16008117)
    • (1986) Science , vol.233 , Issue.4760 , pp. 212-214
    • Ben-Neriah, Y.1    Daley, G.Q.2    Mes-Masson, A.-M.3
  • 4
    • 0000710215 scopus 로고
    • Chromosome studies in human leukemia. II. Chronic granulocytic leukemia
    • Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. JNatl Cancer Inst. 1961;27:1013-35.
    • (1961) JNatl Cancer Inst , vol.27 , pp. 1013-1035
    • Nowell, P.C.1    Hungerford, D.A.2
  • 5
    • 0015694748 scopus 로고
    • Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
    • Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-3.
    • (1973) Nature , vol.243 , pp. 290-293
    • Rowley, J.D.1
  • 6
    • 0025117392 scopus 로고
    • Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
    • Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-30.
    • (1990) Science , vol.247 , pp. 824-830
    • Daley, G.Q.1    Van Etten, R.A.2    Baltimore, D.3
  • 7
    • 0029133211 scopus 로고
    • Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
    • Gaiger A, Henn T, Hörth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86:2371-8.
    • (1995) Blood , vol.86 , pp. 2371-2378
    • Gaiger, A.1    Henn, T.2    Hörth, E.3    Geissler, K.4    Mitterbauer, G.5    Maier-Dobersberger, T.6
  • 8
    • 77954977940 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: Mechanisms of blastic transformation
    • Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120:2254-64.
    • (2010) J Clin Invest , vol.120 , pp. 2254-2264
    • Perrotti, D.1    Jamieson, C.2    Goldman, J.3    Skorski, T.4
  • 9
    • 67349233062 scopus 로고    scopus 로고
    • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    • Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-61.
    • (2009) Leukemia , vol.23 , pp. 1054-1061
    • Hochhaus, A.1    O'Brien, S.G.2    Guilhot, F.3    Druker, B.J.4    Branford, S.5    Foroni, L.6
  • 10
    • 79955018499 scopus 로고    scopus 로고
    • Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia
    • Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634-42.
    • (2011) J Clin Oncol , vol.29 , pp. 1634-1642
    • Hehlmann, R.1    Lauseker, M.2    Jung-Munkwitz, S.3    Leitner, A.4    Müller, M.C.5    Pletsch, N.6
  • 11
    • 84867395848 scopus 로고    scopus 로고
    • Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
    • Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197-203.
    • (2012) Leukemia , vol.26 , pp. 2197-2203
    • Larson, R.A.1    Hochhaus, A.2    Hughes, T.P.3    Clark, R.E.4    Etienne, G.5    Kim, D.W.6
  • 12
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3    Cortes, J.4    Shah, S.5    Ayala, M.6
  • 13
  • 14
    • 81555214617 scopus 로고    scopus 로고
    • Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
    • Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565-72.
    • (2011) Blood , vol.118 , pp. 5565-5572
    • Chu, S.1    McDonald, T.2    Lin, A.3    Chakraborty, S.4    Huang, Q.5    Snyder, D.S.6
  • 15
    • 80053361301 scopus 로고    scopus 로고
    • Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
    • Chomel J-C, Bonnet M-L, Sorel N, Bertrand A, Meunier M-C, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657-60.
    • (2011) Blood , vol.118 , pp. 3657-3660
    • Chomel, J.-C.1    Bonnet, M.-L.2    Sorel, N.3    Bertrand, A.4    Meunier, M.-C.5    Fichelson, S.6
  • 16
    • 84855842631 scopus 로고    scopus 로고
    • Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
    • Shows that imatinib selects for persisting BCR-ABL-positive cells that express comparably low amounts of BCR-ABL mRNA and that these BCR-ABL low cells are not sensitive to TKI
    • • Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119:530-9. Shows that imatinib selects for persisting BCR-ABL-positive cells that express comparably low amounts of BCR-ABL mRNA and that these BCR-ABL low cells are not sensitive to TKI.
    • (2012) Blood , vol.119 , pp. 530-539
    • Kumari, A.1    Brendel, C.2    Hochhaus, A.3    Neubauer, A.4    Burchert, A.5
  • 17
    • 78650949272 scopus 로고    scopus 로고
    • Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
    • Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121:396-409.
    • (2011) J Clin Invest , vol.121 , pp. 396-409
    • Corbin, A.S.1    Agarwal, A.2    Loriaux, M.3    Cortes, J.4    Deininger, M.W.5    Druker, B.J.6
  • 18
    • 84863124648 scopus 로고    scopus 로고
    • Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
    • Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501-10.
    • (2012) Blood , vol.119 , pp. 1501-1510
    • Hamilton, A.1    Helgason, G.V.2    Schemionek, M.3    Zhang, B.4    Myssina, S.5    Allan, E.K.6
  • 20
    • 4644341516 scopus 로고    scopus 로고
    • Discontinuation of imatinib therapy after achieving a molecular response [3]
    • DOI 10.1182/blood-2004-04-1335
    • Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104:2204-5. (Pubitemid 39297882)
    • (2004) Blood , vol.104 , Issue.7 , pp. 2204-2205
    • Cortes, J.1    O'Brien, S.2    Kantarjian, H.3
  • 21
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
    • Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-35.
    • (2010) Lancet Oncol , vol.11 , pp. 1029-1035
    • Mahon, F.-X.1    Réa, D.2    Guilhot, J.3    Guilhot, F.4    Huguet, F.5    Nicolini, F.6
  • 22
    • 84886917643 scopus 로고    scopus 로고
    • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study
    • Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515-22.
    • (2013) Blood , vol.122 , pp. 515-522
    • Ross, D.M.1    Branford, S.2    Seymour, J.F.3    Schwarer, A.P.4    Arthur, C.5    Yeung, D.T.6
  • 23
    • 34249988828 scopus 로고    scopus 로고
    • Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells
    • DOI 10.1182/blood-2006-06-032490
    • Modi H, McDonald T, Chu S, Yee J-K, Forman SJ, Bhatia R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood. 2007;109:5411-21. (Pubitemid 46890564)
    • (2007) Blood , vol.109 , Issue.12 , pp. 5411-5421
    • Modi, H.1    McDonald, T.2    Chu, S.3    Yee, J.-K.4    Forman, S.J.5    Bhatia, R.6
  • 24
    • 84858835938 scopus 로고    scopus 로고
    • BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia
    • Chomel J-C, Sorel N, Guilhot J, Guilhot F, Turhan AG. BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. Blood. 2012;119:2964-5.
    • (2012) Blood , vol.119 , pp. 2964-2965
    • Chomel, J.-C.1    Sorel, N.2    Guilhot, J.3    Guilhot, F.4    Turhan, A.G.5
  • 25
    • 84858807286 scopus 로고    scopus 로고
    • Response: Too much BCRABL to live on, but too little BCR-ABL to die on?
    • Burchert A, Neubauer A, Hochhaus A. Response: Too much BCRABL to live on, but too little BCR-ABL to die on? Blood. 2012;119:2965-6.
    • (2012) Blood , vol.119 , pp. 2965-2966
    • Burchert, A.1    Neubauer, A.2    Hochhaus, A.3
  • 26
    • 4544324306 scopus 로고    scopus 로고
    • Blasts from the past: New lessons in stem cell biology from chronic myelogenous leukemia
    • DOI 10.1016/j.ccr.2004.09.005, PII S1535610804002466
    • Huntly BJP, Gilliland DG. Blasts fromthe past: new lessons in stem cell biology from chronic myelogenous leukemia. Cancer Cell. 2004;6:199-201. (Pubitemid 39222031)
    • (2004) Cancer Cell , vol.6 , Issue.3 , pp. 199-201
    • Huntly, B.J.P.1    Gilliland, D.G.2
  • 27
    • 36649002031 scopus 로고    scopus 로고
    • Loss of beta-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo
    • DOI 10.1016/j.ccr.2007.11.003, PII S1535610807003340
    • Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12:528-41. (Pubitemid 350199070)
    • (2007) Cancer Cell , vol.12 , Issue.6 , pp. 528-541
    • Zhao, C.1    Blum, J.2    Chen, A.3    Kwon, H.Y.4    Jung, S.H.5    Cook, J.M.6    Lagoo, A.7    Reya, T.8
  • 30
    • 33646248661 scopus 로고    scopus 로고
    • Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
    • Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. P Natl Acad Sci Usa. 2006;103:6688-93.
    • (2006) P Natl Acad Sci Usa , vol.103 , pp. 6688-6693
    • Williams, R.T.1    Roussel, M.F.2    Sherr, C.J.3
  • 31
    • 79960505838 scopus 로고    scopus 로고
    • A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia
    • Chen Y, Sullivan C, Peng C, Shan Y, Hu Y, Li D, et al. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood. 2011;118:390-400.
    • (2011) Blood , vol.118 , pp. 390-400
    • Chen, Y.1    Sullivan, C.2    Peng, C.3    Shan, Y.4    Hu, Y.5    Li, D.6
  • 32
    • 67649861052 scopus 로고    scopus 로고
    • Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
    • Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41:783-92.
    • (2009) Nat Genet , vol.41 , pp. 783-792
    • Chen, Y.1    Hu, Y.2    Zhang, H.3    Peng, C.4    Li, S.5
  • 33
    • 0032211172 scopus 로고    scopus 로고
    • The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
    • Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-7. (Pubitemid 28492345)
    • (1998) Blood , vol.92 , Issue.9 , pp. 3362-3367
    • Bose, S.1    Deininger, M.2    Gora-Tybor, J.3    Goldman, J.M.4    Melo, J.V.5
  • 34
    • 0028786297 scopus 로고
    • Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
    • Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86:3118-22.
    • (1995) Blood , vol.86 , pp. 3118-3122
    • Biernaux, C.1    Loos, M.2    Sels, A.3    Huez, G.4    Stryckmans, P.5
  • 36
    • 0023410428 scopus 로고
    • In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
    • McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. P Natl Acad Sci Usa. 1987;84:6558-62.
    • (1987) P Natl Acad Sci Usa , vol.84 , pp. 6558-6562
    • McLaughlin, J.1    Chianese, E.2    Witte, O.N.3
  • 38
    • 0032520986 scopus 로고    scopus 로고
    • Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210(bcr/abl): A novel transgenic model for human Ph-1-positive leukemias
    • HONDA H, Oda H, Suzuki T, Takahashi T, WITTE O, Ozawa K, et al. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210(bcr/abl): a novel transgenic model for human Ph-1-positive leukemias. Blood. 1998;91:2067-75.
    • (1998) Blood , vol.91 , pp. 2067-2075
    • Honda, H.1    Oda, H.2    Suzuki, T.3    Takahashi, T.4    Witte, O.5    Ozawa, K.6
  • 39
    • 0038240346 scopus 로고    scopus 로고
    • Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: Longer disease latency, thrombocytosis, and mild leukocytosis
    • DOI 10.1182/blood-2002-10-3182
    • Inokuchi K, Dan K, Takatori M, Takahuji H, Uchida N, Inami M, et al. Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. Blood. 2003;102:320-3. (Pubitemid 36759671)
    • (2003) Blood , vol.102 , Issue.1 , pp. 320-323
    • Inokuchi, K.1    Dan, K.2    Takatori, M.3    Takahuji, H.4    Uchida, N.5    Inami, M.6    Miyake, K.7    Honda, H.8    Hirai, H.9    Shimada, T.10
  • 40
    • 0142183447 scopus 로고    scopus 로고
    • Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome
    • DOI 10.1182/blood-2003-03-0768
    • Huettner CS, Koschmieder S, Iwasaki H, Iwasaki-Arai J, Radomska HS, Akashi K, et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood. 2003;102:3363-70. (Pubitemid 37314779)
    • (2003) Blood , vol.102 , Issue.9 , pp. 3363-3370
    • Huettner, C.S.1    Koschmieder, S.2    Iwasaki, H.3    Iwasaki-Arai, J.4    Radomska, H.S.5    Akashi, K.6    Tenen, D.G.7
  • 42
    • 84885846261 scopus 로고    scopus 로고
    • Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia
    • First transgenic mouse, in which BCR-ABL is expressed from the enogenous BCR promoter. Supports the concept that BCR-ABL may require cooperating events to induce transformation
    • • Foley SB, Hildenbrand ZL, Soyombo AA, Magee JA, Wu Y, Oravecz-Wilson KI, et al. Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia. Cell Rep. 2013;5:51-60. First transgenic mouse, in which BCR-ABL is expressed from the enogenous BCR promoter. Supports the concept that BCR-ABL may require cooperating events to induce transformation.
    • (2013) Cell Rep , vol.5 , pp. 51-60
    • Foley, S.B.1    Hildenbrand, Z.L.2    Soyombo, A.A.3    Magee, J.A.4    Wu, Y.5    Oravecz-Wilson, K.I.6
  • 44
    • 10944258521 scopus 로고    scopus 로고
    • Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation
    • DOI 10.1016/j.ccr.2004.10.013, PII S1535610804003071
    • Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6:577-86. (Pubitemid 40017701)
    • (2004) Cancer Cell , vol.6 , Issue.6 , pp. 577-586
    • Boxer, R.B.1    Jang, J.W.2    Sintasath, L.3    Chodosh, L.A.4
  • 45
    • 0038107350 scopus 로고    scopus 로고
    • Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations
    • DOI 10.1182/blood-2002-10-3091
    • Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 2003;101:2797-803. (Pubitemid 36857646)
    • (2003) Blood , vol.101 , Issue.7 , pp. 2797-2803
    • Karlsson, A.1    Giuriato, S.2    Tang, F.3    Fung-Weier, J.4    Levan, G.5    Felsher, D.W.6
  • 46
    • 10944228766 scopus 로고    scopus 로고
    • Oncogene addiction: Sometimes a temporary slavery
    • DOI 10.1016/j.ccr.2004.12.002, PII S1535610804003393
    • Jonkers J, Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell. 2004;6:535-8. (Pubitemid 40017696)
    • (2004) Cancer Cell , vol.6 , Issue.6 , pp. 535-538
    • Jonkers, J.1    Berns, A.2
  • 51
    • 40449120350 scopus 로고    scopus 로고
    • An oncogene-induced DNA damage model for cancer development
    • DOI 10.1126/science.1140735
    • Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352-5. (Pubitemid 351354863)
    • (2008) Science , vol.319 , Issue.5868 , pp. 1352-1355
    • Halazonetis, T.D.1    Gorgoulis, V.G.2    Bartek, J.3
  • 52
    • 33845269825 scopus 로고    scopus 로고
    • Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
    • Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638-42.
    • (2006) Nature , vol.444 , pp. 638-642
    • Di Micco, R.1    Fumagalli, M.2    Cicalese, A.3    Piccinin, S.4    Gasparini, P.5    Luise, C.6
  • 53
    • 0030944985 scopus 로고    scopus 로고
    • Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a)
    • DOI 10.1016/S0092-8674(00)81902-9
    • Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593-602. (Pubitemid 27152402)
    • (1997) Cell , vol.88 , Issue.5 , pp. 593-602
    • Serrano, M.1    Lin, A.W.2    McCurrach, M.E.3    Beach, D.4    Lowe, S.W.5
  • 54
    • 9244224723 scopus 로고    scopus 로고
    • Intrinsic tumour suppression
    • DOI 10.1038/nature03098
    • Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004;432:307-15. (Pubitemid 39551658)
    • (2004) Nature , vol.432 , Issue.7015 , pp. 307-315
    • Lowe, S.W.1    Cepero, E.2    Evan, G.3
  • 59
    • 84863011183 scopus 로고    scopus 로고
    • Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stemcells in combination with imatinib
    • Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stemcells in combination with imatinib. Cancer Cell. 2012;21:266-81.
    • (2012) Cancer Cell , vol.21 , pp. 266-281
    • Li, L.1    Wang, L.2    Li, L.3    Wang, Z.4    Ho, Y.5    McDonald, T.6
  • 60
    • 77951667031 scopus 로고    scopus 로고
    • Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway
    • Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis. 2010;15:608-20.
    • (2010) Apoptosis , vol.15 , pp. 608-620
    • Kurosu, T.1    Wu, N.2    Oshikawa, G.3    Kagechika, H.4    Miura, O.5
  • 61
    • 79955830260 scopus 로고    scopus 로고
    • p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
    • Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25:761-9.
    • (2011) Leukemia , vol.25 , pp. 761-769
    • Peterson, L.F.1    Mitrikeska, E.2    Giannola, D.3    Lui, Y.4    Sun, H.5    Bixby, D.6
  • 62
    • 13944273471 scopus 로고    scopus 로고
    • p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression
    • DOI 10.1038/ncb1211
    • Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol. 2005;7:165-71. (Pubitemid 40268131)
    • (2005) Nature Cell Biology , vol.7 , Issue.2 , pp. 165-171
    • Lin, T.1    Chao, C.2    Saito, S.3    Mazur, S.J.4    Murphy, M.E.5    Appella, E.6    Xu, Y.7
  • 63
    • 0037711685 scopus 로고    scopus 로고
    • Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice
    • DOI 10.1016/S0301-472X(03)00072-9
    • TeKippe M, Harrison DE, Chen J. Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol. 2003;31:521-7. (Pubitemid 36793959)
    • (2003) Experimental Hematology , vol.31 , Issue.6 , pp. 521-527
    • TeKippe, M.1    Harrison, D.E.2    Chen, J.3
  • 64
    • 43449084346 scopus 로고    scopus 로고
    • Arf-/- multipotent progenitors
    • DOI 10.1038/nature06869, PII NATURE06869
    • Akala OO, Park I-K, Qian D, Pihalja M, Becker MW, Clarke MF. Long-term haematopoietic reconstitution by Trp53-/- p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature. 2008;453:228-32. (Pubitemid 351667977)
    • (2008) Nature , vol.453 , Issue.7192 , pp. 228-232
    • Akala, O.O.1    Park, I.-K.2    Qian, D.3    Pihalja, M.4    Becker, M.W.5    Clarke, M.F.6
  • 66
    • 69349098834 scopus 로고    scopus 로고
    • Stem cells: The promises and perils of p53
    • Krizhanovsky V, Lowe SW. Stem cells: the promises and perils of p53. Nature. 2009;460:1085-6.
    • (2009) Nature , vol.460 , pp. 1085-1086
    • Krizhanovsky, V.1    Lowe, S.W.2
  • 67
    • 0033552813 scopus 로고    scopus 로고
    • The oncogene and Polycombgroup gene bmi-1 regulates cell proliferation and senescence through the ink4a locus
    • DOI 10.1038/16476
    • Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164-8. (Pubitemid 29050921)
    • (1999) Nature , vol.397 , Issue.6715 , pp. 164-168
    • Jacobs, J.L.1    Kieboom, K.2    Marino, S.3    DePinho, R.A.4    Van Lohuizen, M.5
  • 69
    • 44849129491 scopus 로고    scopus 로고
    • Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
    • DOI 10.1101/gad.1673908
    • Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008;22:1411-5. (Pubitemid 351793074)
    • (2008) Genes and Development , vol.22 , Issue.11 , pp. 1411-1415
    • Mullighan, C.G.1    Williams, R.T.2    Downing, J.R.3    Sherr, C.J.4
  • 72
    • 76249087423 scopus 로고    scopus 로고
    • TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
    • Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463:676-80.
    • (2010) Nature , vol.463 , pp. 676-680
    • Naka, K.1    Hoshii, T.2    Muraguchi, T.3    Tadokoro, Y.4    Ooshio, T.5    Kondo, Y.6
  • 73
    • 80055108071 scopus 로고    scopus 로고
    • BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
    • This article shows that bcl-6 limits tumorsuppressive responses by transcriptional suppression of p53 and Arf in a CML mouse model
    • • Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim Y-M, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208:2163-74. This article shows that bcl-6 limits tumorsuppressive responses by transcriptional suppression of p53 and Arf in a CML mouse model.
    • (2011) J Exp Med , vol.208 , pp. 2163-2174
    • Hurtz, C.1    Hatzi, K.2    Cerchietti, L.3    Braig, M.4    Park, E.5    Kim, Y.-M.6
  • 74
    • 79956305728 scopus 로고    scopus 로고
    • BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
    • Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011;473:384-8.
    • (2011) Nature , vol.473 , pp. 384-388
    • Duy, C.1    Hurtz, C.2    Shojaee, S.3    Cerchietti, L.4    Geng, H.5    Swaminathan, S.6
  • 75
    • 84863116364 scopus 로고    scopus 로고
    • Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis
    • Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood. 2012;119:1904-14.
    • (2012) Blood , vol.119 , pp. 1904-1914
    • Yuan, H.1    Wang, Z.2    Li, L.3    Zhang, H.4    Modi, H.5    Horne, D.6
  • 76
    • 84873441292 scopus 로고    scopus 로고
    • Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation
    • Tomasetti C, Vogelstein B, Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. P Natl Acad Sci Usa. 2013;110:1999-2004.
    • (2013) P Natl Acad Sci Usa , vol.110 , pp. 1999-2004
    • Tomasetti, C.1    Vogelstein, B.2    Parmigiani, G.3
  • 77
    • 34249676964 scopus 로고    scopus 로고
    • Chronic myeloid leukaemia as a model of disease evolution in human cancer
    • DOI 10.1038/nrc2147, PII NRC2147
    • Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-53. (Pubitemid 46823444)
    • (2007) Nature Reviews Cancer , vol.7 , Issue.6 , pp. 441-453
    • Melo, J.V.1    Barnes, D.J.2
  • 78
    • 33644525274 scopus 로고    scopus 로고
    • Gene expression changes associated with progression and response in chronic myeloid leukemia
    • Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. P Natl Acad Sci Usa. 2006;103:2794-9.
    • (2006) P Natl Acad Sci Usa , vol.103 , pp. 2794-2799
    • Radich, J.P.1    Dai, H.2    Mao, M.3    Oehler, V.4    Schelter, J.5    Druker, B.6
  • 80
    • 34247897276 scopus 로고    scopus 로고
    • Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
    • DOI 10.1038/ncb1567, PII NCB1567
    • Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9:493-505. (Pubitemid 46696530)
    • (2007) Nature Cell Biology , vol.9 , Issue.5 , pp. 493-505
    • Sarkisian, C.J.1    Keister, B.A.2    Stairs, D.B.3    Boxer, R.B.4    Moody, S.E.5    Chodosh, L.A.6
  • 81
    • 56849093474 scopus 로고    scopus 로고
    • Distinct thresholds govern Myc's biological output in vivo
    • As one of three earlier publications it shows that oncogene levels critically determine biological output. Whereas high oncogene level lead to engagement of tumor suppressive barriers low level don't. This suggests that the maintenance of low level oncogenic activity is tumor suppressive
    • •• Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell. 2008;14:447-57. As one of three earlier publications it shows that oncogene levels critically determine biological output. Whereas high oncogene level lead to engagement of tumor suppressive barriers low level don't. This suggests that the maintenance of low level oncogenic activity is tumor suppressive.
    • (2008) Cancer Cell , vol.14 , pp. 447-457
    • Murphy, D.J.1    Junttila, M.R.2    Pouyet, L.3    Karnezis, A.4    Shchors, K.5    Bui, D.A.6
  • 83
    • 0037025173 scopus 로고    scopus 로고
    • Cancer: Addiction to oncogenes - The Achilles heal of cancer
    • DOI 10.1126/science.1073096
    • Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 2002;297:63-4. (Pubitemid 34743088)
    • (2002) Science , vol.297 , Issue.5578 , pp. 63-64
    • Weinstein, I.B.1
  • 84
    • 84055179140 scopus 로고    scopus 로고
    • Chronic myeloid leukemia stem cells in the era of targeted therapies: Resistance, persistence and long-term dormancy
    • Chomel J-C, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011;2:713-27.
    • (2011) Oncotarget , vol.2 , pp. 713-727
    • Chomel, J.-C.1    Turhan, A.G.2
  • 85
    • 77958000220 scopus 로고    scopus 로고
    • Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype
    • Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, et al. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. Leukemia. 2010;24:1817-21.
    • (2010) Leukemia , vol.24 , pp. 1817-1821
    • Grant, H.1    Jiang, X.2    Stebbing, J.3    Foroni, L.4    Craddock, C.5    Griffiths, M.6
  • 86
    • 34249693090 scopus 로고    scopus 로고
    • Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
    • DOI 10.1093/jnci/djk150
    • Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronicmyeloid leukemia stem cells. J Natl Cancer Inst. 2007;99:680-93. (Pubitemid 47073530)
    • (2007) Journal of the National Cancer Institute , vol.99 , Issue.9 , pp. 680-693
    • Jiang, X.1    Saw, K.M.2    Eaves, A.3    Eaves, C.4
  • 87
    • 77957196195 scopus 로고    scopus 로고
    • Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
    • Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, Yip C, et al. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 2010;116:2112-21.
    • (2010) Blood , vol.116 , pp. 2112-2121
    • Jiang, X.1    Forrest, D.2    Nicolini, F.3    Turhan, A.4    Guilhot, J.5    Yip, C.6
  • 88
    • 0036090222 scopus 로고    scopus 로고
    • Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
    • Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-25.
    • (2002) Blood , vol.99 , pp. 319-325
    • Graham, S.M.1    Jørgensen, H.G.2    Allan, E.3    Pearson, C.4    Alcorn, M.J.5    Richmond, L.6
  • 89
    • 34247329753 scopus 로고    scopus 로고
    • + CML cells
    • DOI 10.1182/blood-2006-11-057521
    • Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood. 2007;109:4016-9. (Pubitemid 46641755)
    • (2007) Blood , vol.109 , Issue.9 , pp. 4016-4019
    • Jorgensen, H.G.1    Allan, E.K.2    Jordanides, N.E.3    Mountford, J.C.4    Holyoake, T.L.5
  • 90
    • 33744486584 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
    • DOI 10.1182/blood-2005-07-2947
    • Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532-9. (Pubitemid 43801382)
    • (2006) Blood , vol.107 , Issue.11 , pp. 4532-4539
    • Copland, M.1    Hamilton, A.2    Elrick, L.J.3    Baird, J.W.4    Allan, E.K.5    Jordanides, N.6    Barow, M.7    Mountford, J.C.8    Holyoake, T.L.9
  • 91
  • 92
    • 84869090342 scopus 로고    scopus 로고
    • High activity of sorafenib in FLT3-ITD-positive acutemyeloid leukemia synergizes with allo-immune effects to induce sustained responses
    • Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, et al. High activity of sorafenib in FLT3-ITD-positive acutemyeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012.
    • (2012) Leukemia
    • Metzelder, S.K.1    Schroeder, T.2    Finck, A.3    Scholl, S.4    Fey, M.5    Götze, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.